Ensysce生物科学获得1 400万美元NIH/NIDA赠款,用于开发滥用-耐药性、过量保护类阿片PF614-MPAR。 Ensysce Biosciences receives $14m NIH/NIDA grant to develop abuse-deterrent, overdose-protected opioid PF614-MPAR.

Ensysce生物科学公司是一家临床药厂,从NIH和NIDA收到一笔1 400万美元的多年期赠款,用于开发PF614-MPAR,这是一种滥用耐药性和剂量过量保护的类阿片。 Ensysce Biosciences, a clinical-stage pharma firm, received a $14m multi-year grant from NIH and NIDA to develop PF614-MPAR, an opioid with abuse-deterrence and overdose protection. 这种新药于2024年1月获得FDA的突破性治疗指标. This novel drug received Breakthrough Therapy designation from the FDA in Jan 2024. 这笔赠款将有助于完成第一阶段b临床试验,并有助于将PF614-MPAR定位为第一个口服过剂量保护类阿片产品。 The grant will aid the completion of a Phase 1b clinical trial and contribute to positioning PF614-MPAR as the first opioid product with oral overdose protection. Ensysce的MPAR技术可能超越类阿片,以提高药物安全。 Ensysce's MPAR technology may extend beyond opioids to improve drug safety.